 |
Cutting Edge Cancer Care: The Latest on STI-571
|
 |
|
| |
Submitted By: Ariel Borkowsky
Participants:
Brian J. Druker, MD ; Director, Leukemia Center at Oregon Health Sciences University
Charles L. Sawyers, MD ; UCLA Jonsson Cancer Center , Los Angeles, CA
Charles Schiffer, MD ; Karmanos Cancer Institute , Detroit, Michigan
With its recent FDA approval, STI-571 was a hot topic at this year's meeting of the American Society of Clinical Oncology. Designed specifically for chronic myeloid leukemia, it takes a novel, targeted approach to killing cancer cells. But though it has been approved, it is still under investigation. We talked to leading experts at the ASCO meeting to get the most up-to-date information.
Click here to view webcast:
Cutting Edge Cancer Care: The Latest on STI-571
|
|
|
|
Additional Authors: |
|
|
|
|
Works Cited: |
|
|
|
|
Article Links: |
|
|
|
___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___
___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___
___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___
|
|
|
|
|
These review articles are the opinions of the authors. Some of the views may be controversial.
CancerNews.com™ does not directly endorse the work. We merely present it as part of our service.
Please read the disclaimer.
|
|
|
|
|
|
|
|
|
|
Team5 Corporation located in Manhattan (New York) is a Web Development company specializing in
large scale database driven web sites.
{www.team5.com}
|
|
|
|
|
Search for great prices on apparel, electronics, sporting goods and more.
Buy online and save.
{www.shoppingnews.com}
|
|
|
|
